Ligand-induced dimerization of growth factor receptors: Variations on the theme

Cytokine and Growth Factor Reviews

Volumn 7, Issue 1, 1996, Pages 3-10

  Heldin, Carl Henrik ^a   Östman, Arne ^a  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Sweden)

Author keywords

Dimerization; Kinases; Ligand binding; Receptors

Indexed keywords

CYTOKINE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR RECEPTOR; GROWTH HORMONE RECEPTOR; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; LIGAND; PLATELET DERIVED GROWTH FACTOR RECEPTOR; POLYPEPTIDE; PROTEIN TYROSINE KINASE;

BINDING AFFINITY; CHEMISTRY; COMPARATIVE STUDY; DIMERIZATION; DRUG DESIGN; ENZYME ACTIVATION; HUMAN; LIGAND BINDING; MOLECULAR INTERACTION; RECEPTOR BINDING; SHORT SURVEY;

EID: 0030183048     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/1359-6101(96)00002-0     Document Type: Short Survey

References (59)

1. 1. Pawson T. Protein modules and signalling networks. Nature 1995, 373, 573-580.
2. 2. Taniguchi T. Cytokine signaling through nonreceptor protein tyrosine kinases. Science 1995, 268, 251-255
3. 3. ten Dijke P, Miyazono K, Heldin C-H. Signaling via heterooligomeric complexes of type I and type II serine/threonine kinase receptors. Curr Opin Cell Biol (in press).
4. 4. Yarden Y, Schlessinger J. Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry 1987, 26, 1443-1451.
5. 5. Heldin C-H, Ernlund A, Rorsman C, Rönnstrand L. Dimerization of B-type platelet-derived growth factor receptors occurs after ligand binding and is closely asociated with receptor kinase activation. J Biol Chem 1989, 264, 8905-8912.
6. 6. Cunningham BC, Ultsch M, De Vos AM, Mulkerrin MG, Clausner KR, Wells JA. Dimerization of the extracellular domain of the human growth hormone receptor by a single hormone molecule. Science 1991, 254, 821-825.
7. 7. Kanakaraj P, Raj S, Khan SA, Bishayee S. Ligand-induced interaction between α-and β-type platelet derived growth factor (PDGF) receptors: role of receptor heterodimers in kinase activation. Biochemistry 1991, 30, 1761-1767.
8. 8. Seifert RA, Hart CE, Philips PE, Forstrom JW, Ross R, Murray M, et al. Two different subunits associate to create isoform-specific platelet-derived growth factor receptors. J Biol Chem 1989, 264, 8771-8778.
9. 9. Rupp E, Siegbahn A, Rönnstrand L, Wernstedt C, Claesson-Welsh L, Heldin C-H. A unique autophosphorylation site in the platelet-derived growth factor a receptor from a heterodimeric receptor complex. Eur J Biochem 1994, 225, 29-41.
10. 10. Guy PM, Platko JV, Cantely LC, Cerione RA, Carraway KL III. Insect cell-expressed p180(erbB3) possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci USA 1994, 91, 8132-8136.
11. 11. Prigent SA, Gullick WJ. Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J 1994, 13, 2831-2841.
12. 12. Karungagaran D, Tzahar E, Liu N, Wen D, Yarden Y. Neu differentiation factor inhibits EGF binding. A model for trans-regulation within the ErbB family of receptor tyrosine kmases. J Biol Chem 1995, 270, 9982-9990.
13. 13. Fedi P, Pierce JH, Di Fiore PP, Kraus MH. Efficient coupling with phosphatidylinositol 3-kinase, but not phospholipase Cγ or GTPase-activating protein, distinguishes ErbB-3 signaling from that of other ErbB/EGFR family members. Mol Cell Biol 1994, 14, 492-500.
14. 14. Soltoff SP, Carraway KL III, Prigent SA, Gullick WG, Cantley LC. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 1994, 14, 3550-3558.
15. 15. Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J. Mechanism of activation of the TGF-β receptor. Nature 1994, 370, 341-347.
16. 16. Walter MR, Windsor WT, Nagabhushan TL, Lundell DJ, Lunn CA, Zauodny PJ, et al. Crystal structure of a complex between interferon-γ and its soluble high-affinity receptor. Nature 1995, 376, 230-235.
17. 17. Andersson M, Östman A, Kreysing J, Bäckström G, van de Poll M, Heldin C-H. Involvement of loop 2 of platelet-derived growth factor-AA and -BB in receptor binding. Growth Factors 1995, 12, 159-164.
18. 18. Herren B, Rooney B, Weyer KA, Iberg N, Schmid G, Pech M. Dimerization of extracellular domains of platelet-derived growth factor receptors. J Biol Chem 1993, 268, 15088-15095.
19. 19. De Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptors: crystal structure of the complex. Science 1992, 255, 306-312.
20. 20. Ultsch M, De Vos AM, Kossiakoff AA. Crystals of the complex between human growth hormone and the extra-cellular domain of its receptors. J Mol Biol 1991, 22, 865-868.
21. 21. Duquesnoy P, Sobrier M-L, Duriez B, Dastot F, Buchanan CR, Savage MO, et al. A single amino acid substitution in the exoplasmic domain of the human growth hormone (GH) receptor confers familial GH resistance (Laron syndrome) with positive GH-binding activity by abolishing receptor homodimerization. EMBO J 1994, 13, 1386-1395.
22. 22. Watowich SS, Yoshimura A, Longmore GD, Hilton DJ, Yoshimura Y, Lodish HF. Homodimerization and constitutive activation of the erythropoietin receptor. Proc Natl Acad Sci USA 1992, 89, 2140-2144.
23. 23. Alexander WS, Metcalf D, Dunn AR. Point mutations within a dimer interface homology domain of c-Mp1 induce constitutive receptor activity and tumorigenicity. EMBO J 1995, 14, 5569-5578.
24. 24. Blechman JM, Lev S, Barg J, Eisenstein M, Vaks B, Vogel Z, et al. The fourth immunoglobin domain of the stem cell factor receptor couples ligand binding to signal transduction. Cell 1995, 80, 105-115.
25. 25. Lemmon MA, Schlessinger J. Regulation of signal transduction and signal diversity by receptor oligomerization. Trends Biochem Sci 1994, 19, 459-463.
26. 26. Shing Y, Christofori G, Hanahan D, Ono Y, Sasada R, Igarashi K, et al. Betacellulin: a mitogen from pancreatic β-cell tumors. Science 1993, 259, 1604-1607.
27. 27. Yamashita H, ten Dijke P, Franzén P, Miyazono K, Heldin C-H. Formation of hetero-oligomeric complexes of type I and type II receptors for transforming growth factor-β. J Biol Chem 1994, 269, 20172-20178.
28. 28. Massagué J, Attisano L, Wrana JL. The TGF-β family and its composite receptors. Trends Cell Biol 1994, 4, 172-178.
29. 29. Paonessa G, Grazini R, De Serio A, Savino R, Ciapponi L, Lahm A, et al. Two distinct and independent sites of IL-6 trigger gp130 dimer formation and signalling. EMBO J 1995, 14, 1942-1951.
30. 30. Ward LD, Howlett GJ, Discolo G, Yasukawa K, Hammacher A, Moritz RL, et al. High-affinity interleukin-6 receptor is a hexameric complex consisting of two molecules each of interleukin-6, interleukin-6 receptor, and gp-130. J Biol Chem 1994, 269, 23286-23289.
31. 31. Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsude T, et al. Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 1989, 58, 573-581.
32. 32. Murakami M, Hibi M, Nakagawa N, Nakagawa T. Yasukawa K, Yamanishi K, et al. IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase. Science 1993, 260, 1808-1810.
33. 33. Pantoliano MW, Horlick RA, Springer BA, Van Dyk DE, Tobery T, Wetmore DR, et al. Multivalent ligand-receptor binding interactions in the fibroblast growth factor system produce a co-operative growth factor and heparin mechanism for receptor dimerization. Biochemistry 1994, 33, 10229-10248.
34. 34. Springer BA, Pantoliano MW, Barbera FA, Gunyuzlu PL, Thompson LD, Herblin WF, et al. Identification and concerted function of two receptor binding surfaces on basic fibroblast growth factor required for mitogenesis. J Biol Chem 1994, 269, 26879-26884.
35. 35. Maccarana M, Casu B, Lindahl U. Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. J Biol Chem 1993, 268, 23898-23905.
36. 36. Guimond S, Maccarana M, Olwin BB, Lindahl U, Rapraeger AC. Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4. J Biol Chem 1993, 268, 23906-23914.
37. 37. Ishihara M, Tyrrell DJ, Stauber GB, Brown S, Cousens LS, Stack RJ. Preparation of affinity-fractioned, heparinderived oligosaccharides and their effects on selected biological activities mediated by basic fibroblast growth factor. J Biol Chem 1993, 268, 4675-4683.
38. 38. Tyrrell DJ, Ishihara M, Rao N, Horne A, Kiefer MC, Stauber GB, et al. Structure and biological activities of a heparin-derived hexasaccharide with high affinity for basic fibroblast growth factor. J Biol Chem 1993, 268, 4684-4689.
39. 39. Spivak-Kroizman T, Lemmon MA, Dikic I, Ladbary JE, Pinchasi D, Huang J, et al. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell 1994, 79, 1015-1024.
40. 40. Ornitz DM, Herr AB, Nilsson M, Westman J, Svahn C-M, Waksman G. FGF binding and FGF receptor activation by synthetic heparan-derived di-and trisaccharides. Science 1995, 268, 432-436.
41. 41. Gao G, Goldfarb M. Heparin can activate a receptor tyrosine kinase. EMBO J 1995, 14, 2183-2190.
42. 42. Brambilla R, Schnapp A, Casagranda F, Labrador JP, Bergemann AD, Flanagan JG, et al. Membrane-bound LERK2 ligand can signal enough through three different Eph-related receptor tyrosine kinases. EMBO J 1995, 14, 3116-3126.
43. 43. Davis S, Gale NW, Aldrich TH, Maisonpierre PC, Lhotak V, Pawson T, et al. Ligands for EPH-related receptor tyrosine kinases that require membrane attachment or clustering for activity. Science 1994, 266, 816-189.
44. 44. Amaya E, Musci TJ, Kirschner MW. Expression of a dominant negative mutant of the FGF receptor disrupts mesoderm formation in Xenopus embryos. Cell 1991, 66, 257-270.
45. 45. Werner S, Weinberg W, Liao X, Peters KG, Blessing M, Yuspa SH, et al. Targeted expression of a dominant-negative FGF receptor mutant in the epidermis of transgenic mice reveals a role of FGF in keratinocyte organization and differentiation. EMBO J 1993, 12, 2635-2643.
46. 46. Murillas R, Larcher F, Conti CJ, Santos M, Ullrich A, Jorcano JL. Expression of a dominant negative mutant of epidermal growth factor in the epidermis of transgenic mice elicits striking alterations in hair follicle development and skin structure. EMBO J 1995, 14, 5216-5223.
47. 47. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994, 367, 576-579.
48. 48. Fun G, Cunningham BC, Fukunaga R, Nagata S, Goeddel DV, Wells JA. Rational design of potent antagonists to the human growth hormone receptor. Science 1992, 256, 1677-1680.
49. 49. Brakenhoff JPJ, de Hon FD, Fontaine V, ten Boekel E, Schooltink H, Rose-John S, et al. Development of a human interleukin-6 receptor antagonist. J Biol Chem 1994, 269, 86-93.
50. 50. Savino R, Lahm A, Salvati AL, Ciapponi L, Sporeno E, Altamura S, et al. Generation of interleukin-6 receptor antagonists by molecular-modeling guided mutagenesis of residues important for gp 130 activation. EMBO J 1994, 13, 1357-1367.
51. 51. Savino R, Ciapponi L, Lahm A, Demartis A, Cabibbo A, Toniatti C, et al. Rational design of a receptor super-antagonist of human interleukin-6. EMBO J 1994, 13, 5863-5870.
52. 52. Hercus TR, Bagley CJ, Cambarei B, Dottore M, Woodcock JM, Vadas MA, et al. Specific human granulocyte-macrophage colony-stimulating factor antagonists. Proc Natl Acad Sci USA 1994, 91, 5838-5842.
53. 53. Tavernier J, Tuypens T, Verhee A, Plaetinck G, Devos R, Van der Heyden J, et al. Identification of receptor-binding domains on human interleukin 5 and design of an interleukin 5-derived receptor antagonist. Proc Natl Acad Sci USA 1995, 92, 5194-5198.
54. 54. Kruse N, Shen B-J, Arnold S, Tony H-P, Müller T, Sebald W. Two distinct functional sites of human interleukin-4 are identified by variants impaired in either receptor binding or receptor activation. EMBO J 1993, 12, 5121-5129.
55. 55. Kruse N, Tony H-P, Sebald W. Conversion of human interleukin-4 into a high-affinity antagonist by a single amino acid replacement. EMBO J 1992, 11, 3237-3244.
56. 56. Mercola M, Deininger PL, Shamah SM, Porter J, Wang CY, Stiles CD. Dominant-negative mutants of a platelet-derived growth factor gene. Genes Dev 1990, 4, 2333-2341.
57. 57. Vassbotn FS, Andersson M, Westermark B, Heldin C-H, Östman A. Reversion of autocrine transformation by a dominant negative platelet-derived growth factor mutant. Mol Cell Biol 1993, 13, 4066-4076.
58. 58. Shamah SM, Stiles CD, Guha A. Dominant-negative mutants of platelet-derived growth factor revert the transformed phenotype of human astrocytoma cells. Mol Cell Biol 1993, 13, 7203-7212.
59. 59. Heldin C-H. Dimerization of cell surface receptors in signal transduction. Cell 1995, 80, 213-223.